N🟁N

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Silverleaf Resorts, Inc.

  //business-finance.news-articles.net/content/201 .. f-the-acquisition-of-silverleaf-resorts-inc.html
  Published in Business and Finance on Thursday, February 10th 2011 at 11:00 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

NEW YORK--([ BUSINESS WIRE ])--Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Silverleaf Resorts, Inc. (NASDAQ: [ SVLF ]) (referred to as "Silverleaf" or the aCompanya) by an affiliate of Cerberus Capital Management, L.P. (aCerberusa) in a cash transaction valued at approximately $94.4 million.

Under the terms of the agreement, Silverleaf shareholders will receive, at the closing, $2.50 in cash for each share of Silverleaf common stock they own.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Companya™s shareholders. If you are a holder of Silverleaf stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Silverleaf and would like more information about our investigation, please contact Peter D. Bull, Esq. by telephone at (212) 213-6222 or by sending an e-mail including your contact information to: [ counsel@nyclasslaw.com ]. All e-mail correspondence should make reference to Silverleaf.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at [ www.nyclasslaw.com ].

ATTORNEY ADVERTISING.© 2011 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41^st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter.